Printable Copy |
Summary below; full text is at
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30544-8/fulltext
The Lancet Infectious Diseases, Volume 17, No. 4, p358–359, April 2017
Comment
,
Alison P GalvaniEmail the author Alison P Galvani
Published: 21 December 2016
Open Access
DOI: http://dx.doi.org/10.1016/S1473-3099(16)30544-8
Lymphatic filariasis is one of the most debilitating neglected tropical diseases, the clinical manifestations of which include painful and incapacitating lymphoedema.1 Among the estimated 68 million people infected, 36 million are microfilaria carriers and 40 million are symptomatic.1Additionally, 946 million people live in areas of southeast Asia and sub-Saharan Africa where mosquito-borne filariasis is endemic and are, therefore, at risk of infection.1 In 2000, WHO launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF), which aims to interrupt transmission of lymphatic filariasis by 2020.